Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2015 Nov 9:13:314.
doi: 10.1186/s12957-015-0726-z.

Expression of activated signal transducer and activator of transcription-3 as a predictive and prognostic marker in advanced esophageal squamous cell carcinoma

Chuying Huang  1   2 , Li Wang  3 , Xibiao Yang  4 , Lin Lai  5 , Dian Chen  6 , Chunyan Duan  7
Affiliations

Expression of activated signal transducer and activator of transcription-3 as a predictive and prognostic marker in advanced esophageal squamous cell carcinoma

Chuying Huang et al. World J Surg Oncol. .

Abstract

Background: Signal transducer and activator of transcription-3 (STAT3) is an oncogenic transcription factor constitutively active and aberrantly expressed in various types of malignancies, and the expression of p-STAT3 has been recognized as a predictor of poor survival. It remains unclear how variations in p-STAT3 expression influence clinical outcomes in esophageal squamous cell carcinoma (ESCC).

Methods: Between 1 January 2008 and 1 November 2013, 153 advanced esophageal squamous cell carcinoma patients (stage IV) from two cancer centers in West China were treated with paclitaxel and cisplatin. We retrospectively analyzed the clinical outcomes of patients with ESCC and examined the correlation between p-STAT3 levels and clinical outcomes in esophageal cancer patients.

Results: Among the 153 patients, positive p-STAT3 expression was observed in 73 of 153 (47.7 %) cases. The median PFS for patients with positive expression of p-STAT3 and negative expression of p-STAT3 was 5.0 months and 6.9 months, respectively (P < 0.001). The median overall survival was significantly higher in patients with p-STAT3 negative tumors than in those with p-STAT3 positive tumors (9.9 vs 8.9 months, P = 0.026). Kaplan-Meier survival analysis showed that p-STAT3 expression was statistically indicative of a poor prognosis for progression-free survival.

Conclusions: These data showed that p-STAT3 expression was significantly associated with poor prognosis in patients with esophageal cancer and could be used as a predictive and prognostic marker in esophageal cancer.

PubMed Disclaimer

Figures

Fig. 1
Fig. 1
IHC pictures: a. Predominantly the cytoplasmic staining of p-STAT3 in esophageal squamous cell cancer (SP method, ×100). b. p-STAT3 negative expression in esophageal squamous cell cancer (SP method, ×100)
Fig. 2
Fig. 2
Kaplan–Meier curves showing median progress free survival (mPFS) for 153 metastasis esophageal cancer patients treated with paclitaxel and cisplatin according to p-STAT3 levels. The median PFS for patients with positive expression of p-STAT3 and negative expression of p-STAT3 was 5.0 months and 6.9 months, respectively (HR 1.380, 95 % CI 0.698 to 2.062, p < 0.001)
Fig. 3
Fig. 3
Kaplan–Meier curves showing median overall survival (mOS) for 153 metastasis esophageal cancer patients treated with paclitaxel and cisplatin according to p-STAT3 levels. The median overall survival was significantly higher in patients with p-STAT3 negative tumors than in those with p-STAT3-positive tumors (9.9 vs 8.9 months, HR 1.112, 95 % CI 0.4305 to 1.794, p = 0.026)
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Feng XS, Yang YT, Gao SG, Ru Y, Wang GP, Zhou B, et al. Prevalence and age, gender and geographical area distribution of esophageal squamous cell carcinomas in North China from 1985 to 2006. Asian Pac J Cancer Prev. 2014;15:1981–7. doi: 10.7314/APJCP.2014.15.5.1981. - DOI - PubMed
    1. Allum WH, Stenning SP, Bancewicz J, Clark PI, Langley RE. Long-term results of a randomized trial of surgery with or without preoperative chemotherapy in esophageal cancer. J Clin Oncol. 2009;27:5062–7. doi: 10.1200/JCO.2009.22.2083. - DOI - PubMed
    1. Sjoquist KM, Burmeister BH, Smithers BM, Zalcberg JR, Simes RJ, Barbour A, et al. Survival after neoadjuvant chemotherapy or chemoradiotherapy for resectable oesophageal carcinoma: an updated meta-analysis. Lancet Oncol. 2011;12:681–92. doi: 10.1016/S1470-2045(11)70142-5. - DOI - PubMed
    1. Hulscher JB, van Sandick JW, de Boer AG, Wijnhoven BP, Tijssen JG, Fockens P, et al. Extended transthoracic resection compared with limited transhiatal resection for adenocarcinoma of the esophagus. N Engl J Med. 2002;347:1662–9. doi: 10.1056/NEJMoa022343. - DOI - PubMed
    1. Chen M-F, Chen P-T, Lu MS, et al. IL-6 expression predicts treatment response and outcome in squamous cell carcinoma of the esophagus. Mol Cancer. Huo YQ1, Ruan X, DU XL, Shang L, Cai Y, Xu X, et al. Overexpression of p-Stat3 and Mcl-1, and their correlation with differentiation and apoptotic resistance in esophageal squamous cell carcinoma. Zhonghua Zhong Liu Za Zhi. 2013;35:579–84. - PubMed

MeSH terms